DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glyset (Miglitol) - Summary



Glyset® miglitol tablets

GLYSET Tablets contain miglitol, an oral alpha-glucosidase inhibitor for use in the management of non-insulin-dependent diabetes mellitus (NIDDM).

GLYSET Tablets, as monotherapy, are indicated as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone. GLYSET may also be used in combination with a sulfonylurea when diet plus either GLYSET or a sulfonylurea alone do not result in adequate glycemic control. The effect of GLYSET to enhance glycemic control is additive to that of sulfonylureas when used in combination, presumably because its mechanism of action is different.

In initiating treatment for NIDDM, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling blood glucose and symptoms of hyperglycemia. The importance of regular physical activity when appropriate should also be stressed. If this treatment program fails to result in adequate glycemic control, the use of GLYSET should be considered. The use of GLYSET must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint.

See all Glyset indications & dosage >>


Media Articles Related to Glyset (Miglitol)

Make the Diagnosis: Burning Shins
Source: MedPage Today Dermatology [2015.02.24]
(MedPage Today) -- A 48-year-old male presents with slowly expanding areas of discoloration on his anterior shins. He does not recall any antecedent trauma, and has been putting nothing on the area. The lesions are sometimes burning and painful, but are overall largely asymptomatic. They have been present for months. Review of systems is unremarkable, with the patient denying night sweats, cough, chills, unintentional weight loss, or gastrointestinal complaints. He has a past medical history of diabetes mellitus type II and is on metformin and follows a strict diet and exercise regimen.

more news >>

Published Studies Related to Glyset (Miglitol)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. [2011.03]
The objective of this study is to examine the efficacy and tolerability of miglitol with respect to improving glycemic control in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylurea treatment. This was a randomized, double-blinded, placebo-controlled, multicenter study.

Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. [2011.03]
Combination therapy with an alpha-glucosidase inhibitor and insulin is commonly performed for type 2 diabetes mellitus. We conducted a placebo-controlled double-blind comparative study to investigate the efficacy of combination therapy with miglitol and insulin...

Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. [2010]
OBJECTIVE: The incidence of the gastrointestinal adverse effects is important to determine as these effects are the reason for lower compliance of alpha-glucosidase inhibitors (alphaGIs). There has been no direct investigation of the adverse effects with acarbose or miglitol, therefore we compared them in healthy subjects... CONCLUSION: Our results suggest that if diabetic patients have constipation, firm stool, or flatus they may be administered miglitol and if they have diarrhea or soft stool they may be administered acarbose.

Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. [2010]
We previously reported that the administration of miglitol after a meal was equally effective as administration before a meal. Since glucagon-like peptide-1 (GLP-1) reportedly promotes islet cell growth and inhibits apoptosis in animal models, an increase in GLP-1 secretion might also be beneficial for islet cell function and mass in humans...

Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. [2008.09]
Visceral obesity and insulin resistance are regarded as risk factors for atherosclerosis. Epidemiologic studies have demonstrated long-term anti-atherosclerotic effects with administration of alpha-glucosidase inhibitors.

more studies >>

Clinical Trials Related to Glyset (Miglitol)

Double-Blind Study of Miglitol in Japanese With type2 Diabetes [Completed]
To investigate the efficacy and safety of miglitol in Japanese patients with type 2 diabetes that is insufficiently controlled diet alone.

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment [Completed]
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type1 Diabetes Mellitus treated with insulin.

Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide [Active, not recruiting]
The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin [Completed]
In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment [Completed]
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.

more trials >>

Page last updated: 2015-02-24

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015